Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 17Genitourinary 11Breast 9Gynecologic 3Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

HER2 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × disitamab vedotin × Other solid neoplasm × Clear all
NCT05649163 2022-12-16

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Peking University

Unknown
306 enrolled
GastrointestinalOther solid neoplasm

HER2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡